Given that cutaneous SCC (cSCC) is a relatively common skin cancer that can metastasize and recur, we aimed to characterize Cornulin as a molecular biomarker that can potentially aid in monitoring disease progression and relapse, as well as predicting clinical outcomes for cSCC patients, by examining the correlation between Cornulin expression and the clinical stages as indicated by the TNM staging of cSCC based on tumor size, regional lymph node involvement, and metastasis. The gene discussed is CRNN; the disease is neoplasm.